A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.

[1]  A. Strasser,et al.  Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome. , 2012, Blood.

[2]  M. Konopleva,et al.  Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors , 2012, Leukemia.

[3]  M. Nöthen,et al.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer , 2012, Nature Medicine.

[4]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[5]  A. Bennaceur-Griscelli,et al.  Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. , 2011, Blood.

[6]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[7]  A. Turhan,et al.  Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy , 2011, Oncotarget.

[8]  Jane E. Visvader,et al.  Cells of origin in cancer , 2011, Nature.

[9]  P. Vyas,et al.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.

[10]  B. Druker,et al.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.

[11]  Pamela A. Silver,et al.  An Alternative Splicing Network Links Cell-Cycle Control to Apoptosis , 2010, Cell.

[12]  E. Domany,et al.  A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. , 2010, Cell stem cell.

[13]  P. Fisher,et al.  BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. , 2010, Journal of medicinal chemistry.

[14]  John Calvin Reed,et al.  A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy , 2010, Cell Death and Disease.

[15]  Derek W. Yecies,et al.  Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. , 2010, Blood.

[16]  C. Heeschen,et al.  Cancer stem cells in solid tumors. , 2010, Seminars in cancer biology.

[17]  Satoshi Tanaka,et al.  Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML , 2010, Nature Biotechnology.

[18]  Joshua M. Stuart,et al.  Molecular Signatures of Quiescent, Mobilized and Leukemia-Initiating Hematopoietic Stem Cells , 2010, PloS one.

[19]  R. Arceci,et al.  A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib , 2010 .

[20]  Li Yang,et al.  Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. , 2009, Journal of medicinal chemistry.

[21]  S. Stuart,et al.  The CML stem cell: Evolution of the progenitor , 2009, Cell cycle.

[22]  M. Butterworth,et al.  Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. , 2009, Blood.

[23]  Tannishtha Reya,et al.  Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia , 2009, Nature.

[24]  I. Weissman,et al.  Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation , 2009, Proceedings of the National Academy of Sciences.

[25]  H. Varmus,et al.  MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family , 2009, Oncogene.

[26]  G. Cohen,et al.  Bcl-2 inhibitors: small molecules with a big impact on cancer therapy , 2009, Cell Death and Differentiation.

[27]  T. Naoe,et al.  Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy , 2008, International journal of hematology.

[28]  D. Boulware,et al.  Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance , 2008, Molecular Cancer Therapeutics.

[29]  John Calvin Reed.  Bcl-2-family proteins and hematologic malignancies: history and future prospects. , 2008, Blood.

[30]  M. Deininger.  Resistance and relapse with imatinib in CML: causes and consequences. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[31]  T. Reya,et al.  Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo , 2007 .

[32]  Dung-Fang Lee,et al.  Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. , 2007, Cancer research.

[33]  P. Dent,et al.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.

[34]  Y. Li,et al.  (–)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells , 2007, Leukemia & lymphoma.

[35]  T. Reya,et al.  Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. , 2007, Cancer cell.

[36]  T. Naoe,et al.  Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice , 2007, Leukemia.

[37]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[38]  J. Melo,et al.  Primitive, Quiescent and Difficult to Kill: The Role of Non-Proliferating Stem Cells in Chronic Myeloid Leukemia , 2006, Cell cycle.

[39]  A. Strasser,et al.  Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic , 2006, Proceedings of the National Academy of Sciences.

[40]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[41]  E. Yang,et al.  BCL2 family in DNA damage and cell cycle control , 2006, Cell Death and Differentiation.

[42]  A. Puisieux,et al.  Metastasis: a question of life or death , 2006, Nature Reviews Cancer.

[43]  Hongyue Dai,et al.  Gene expression changes associated with progression and response in chronic myeloid leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Dutcher,et al.  Blastic phase of chronic myelogenous leukemia , 2005, Current treatment options in oncology.

[45]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[46]  S. Derdak,et al.  Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. , 2005, Blood.

[47]  H. Kantarjian,et al.  Discontinuation of imatinib therapy after achieving a molecular response. , 2004, Blood.

[48]  Yun Dai,et al.  A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2* , 2004, Journal of Biological Chemistry.

[49]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[50]  S. Edwards,et al.  Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications , 2004, Cellular and Molecular Life Sciences CMLS.

[51]  T. Tauchi,et al.  BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  I. Weissman,et al.  Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  I. Weissman,et al.  Hematopoietic stem cells and other hematopoietic cells show broad resistance to chemotherapeutic agents in vivo when overexpressing bcl-2. , 2003, Experimental hematology.

[54]  D. Howard,et al.  Preferential induction of apoptosis for primary human leukemic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[55]  E. Estey,et al.  The anti‐apoptotic genes Bcl‐XL and Bcl‐2 are over‐expressed and contribute to chemoresistance of non‐proliferating leukaemic CD34+ cells , 2002, British journal of haematology.

[56]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[57]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[58]  J. Griffin,et al.  Bcr/Abl activates transcription of the Bcl-X gene through STAT5. , 2000, Blood.

[59]  R. Craig,et al.  Exon Skipping in Mcl-1 Results in a Bcl-2 Homology Domain 3 Only Gene Product That Promotes Cell Death* , 2000, The Journal of Biological Chemistry.

[60]  D. A. Goldman,et al.  Are standardized mortality ratios valid for public health data analysis? , 2000, Statistics in medicine.

[61]  E. Andreu,et al.  Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL , 2000, The Journal of experimental medicine.

[62]  C. Eaves,et al.  Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. , 1999, Blood.

[63]  D. Green,et al.  Bcl-2-independent Bcr–Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL , 1998, Oncogene.

[64]  A. Strasser,et al.  Expression of a bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo. , 1997, Journal of immunology.

[65]  A. Strasser,et al.  bcl-2 transgene expression promotes survival and reduces proliferation of CD3-CD4-CD8- T cell progenitors. , 1997, International immunology.

[66]  A. Strasser,et al.  The cell death inhibitor Bcl‐2 and its homologues influence control of cell cycle entry. , 1996, The EMBO journal.

[67]  C. Eaves,et al.  Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor. , 1996, Blood.

[68]  J. M. Adams,et al.  Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. , 1996, Oncogene.

[69]  I. Sánchez-García,et al.  Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[70]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[71]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[72]  V. Najfeld,et al.  Involvement of the B-lymphoid system in chronic myelogenous leukaemia , 1980, Nature.